{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:17:22Z","timestamp":1792289842375,"version":"4.4.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:p>Direct\u2010acting antiviral agents have not been studied exclusively in patients with inherited blood disorders and hepatitis C virus (HCV) infection. The objective of the randomized, placebo\u2010controlled, phase III C\u2010EDGE IBLD study was to assess the safety and efficacy of elbasvir\/grazoprevir (EBR\/GZR) in patients with inherited bleeding disorders and HCV infection. One hundred fifty\u2010nine adults with HCV infection and sickle cell anemia, thalassemia, or hemophilia A\/B or von Willebrand disease were enrolled at 31 study sites in the United States, Europe, Australia, Canada, Israel, and Thailand. Patients were given an oral, once\u2010daily, fixed\u2010dose combination of EBR\/GZR 50\u2009mg\/100\u2009mg for 12 weeks and randomized to the immediate\u2010treatment group (ITG) or deferred\u2010treatment group (DTG; placebo followed by active treatment). The primary endpoints were the proportion of patients in the ITG with unquantifiable HCV RNA 12 weeks posttreatment (sustained virological response 12 weeks after completion of study treatment; SVR12) and the comparison of safety in the ITG and DTG. In the ITG, 100 of 107 patients (93.5%) achieved SVR12, 6 relapsed, and 1 was lost to follow\u2010up. SVR12 was achieved in 94.7% (18 of 19), 97.6% (40 of 41), and 89.4% (42 of 47) of patients with sickle cell disease, \u03b2\u2010thalassemia, and hemophilia A\/B or von Willebrand disease, respectively. Serious adverse events were reported by 2.8% (n\u2009=\u20093) and 11.5% (n\u2009=\u20096) of patients in the ITG and DTG, respectively. Hemoglobin levels and international normalized ratio values were similar in patients receiving EBR\/GZR and placebo; among patients with hemoglobinopathies, change in mean hemoglobin levels was similar in those receiving EBR\/GZR compared to those receiving placebo. <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: These results add to the expanding pool of data available for EBR\/GZR, indicating a high level of efficacy and favorable tolerability in patients with HCV infection. (H<jats:sc>epatology<\/jats:sc> 2017;66:736\u2013745)<\/jats:p>","DOI":"10.1002\/hep.29139","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T12:47:29Z","timestamp":1488545249000},"page":"736-745","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":68,"title":["Elbasvir\/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study"],"prefix":"10.1097","volume":"66","author":[{"given":"Christophe","family":"H\u00e9zode","sequence":"first","affiliation":[{"name":"Henri Mondor Hospital,Paris,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[{"name":"Humanitas Clinical and Research Center,Rozzano,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bourli\u00e8re","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Joseph,Marseille,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Spengler","sequence":"additional","affiliation":[{"name":"University Hospital Bonn,Bonn,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziv","family":"Ben\u2010Ari","sequence":"additional","affiliation":[{"name":"Sheba Medical Center,Ramat Gan,Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone I.","family":"Strasser","sequence":"additional","affiliation":[{"name":"University of Sydney,Sydney,NSW,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center,Dallas,TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Morgan","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc,Kenilworth,NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjun","family":"Qiu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc,Kenilworth,NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Hwang","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc,Kenilworth,NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Robertson","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc,Kenilworth,NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bach\u2010Yen","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc,Kenilworth,NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliav","family":"Barr","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc,Kenilworth,NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Wahl","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc,Kenilworth,NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Haber","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc,Kenilworth,NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chase","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc,Kenilworth,NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Talwani","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc,Kenilworth,NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Di Marco","sequence":"additional","affiliation":[{"name":"University of Palermo,Palermo,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the C\u2010EDGE IBLD Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,7,20]]},"reference":[{"key":"hep29139-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/gut.47.6.845","article-title":"The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985","volume":"47","year":"2000","journal-title":"Gut"},{"key":"hep29139-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2013.08.010","article-title":"Long\u2010term follow\u2010up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"hep29139-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1182\/blood-2009-11-248724","article-title":"Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel","volume":"116","year":"2010","journal-title":"Blood"},{"key":"hep29139-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD\u2010IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep29139-bib-0005-20241017","first-page":"199","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"hep29139-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/hae.12791","article-title":"Once daily ledipasvir\/sofosbuvir fixed\u2010dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection","volume":"22","year":"2016","journal-title":"Haemophilia"},{"key":"hep29139-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK\u20105172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"hep29139-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/cmdc.201300343","article-title":"Discovery of MK\u20108742: an HCV NS5A inhibitor with broad genotype activity","volume":"8","year":"2013","journal-title":"ChemMedChem"},{"key":"hep29139-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","article-title":"Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK\u20105172) and elbasvir (MK\u20108742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C\u2010WORTHY): a randomised, open\u2010label phase 2 trial","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"hep29139-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","article-title":"Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK\u20105172) and elbasvir (MK\u20108742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono\u2010infection and HIV\/hepatitis C virus co\u2010infection (C\u2010WORTHY): a randomised, open\u2010label phase 2 trial","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"hep29139-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir\u2013elbasvir combination therapy for treatment\u2010naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial","volume":"163","year":"2015","journal-title":"Ann Intern Med"},{"key":"hep29139-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","article-title":"Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype\u20101 infection after failure of combination therapy containing a direct\u2010acting antiviral agent","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"hep29139-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/cid\/civ722","article-title":"Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier\u2010generation protease inhibitor: final 24\u2010week results from C\u2010SALVAGE","volume":"62","year":"2016","journal-title":"Clin Infect Dis"},{"key":"hep29139-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK\u20105172) and elbasvir (MK\u20108742) in patients with hepatitis C virus and HIV co\u2010infection (C\u2010EDGE CO\u2010INFECTION): a non\u2010randomised, open\u2010label trial","volume":"2","year":"2015","journal-title":"Lancet HIV"},{"key":"hep29139-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment\u2010naive and treatment\u2010experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20105 chronic kidney disease (the C\u2010SURFER study): a combination phase 3 study","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"hep29139-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa\u20102b or alfa\u20102a with ribavirin for treatment of hepatitis C infection","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"issue":"1 Suppl","key":"hep29139-bib-0018-20241017","first-page":"554A","article-title":"Predictors of response to grazoprevir\/elbasvir among HCV genotype 1 (GT1)\u2013infected patients: integrated analysis of phase 2\u20103 trials","volume":"62","year":"2015","journal-title":"Hepatology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.29139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201709000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T23:28:10Z","timestamp":1729207690000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201709000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,20]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.29139","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,20]]},"assertion":[{"value":"2016-11-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}